The revival of colistin: An old antibiotic for the 21st century;La colistine: un ancien antibiotique pour le XXI siecle

Pathologie Biologie

Volumn 57, Issue 3, 2009, Pages 229-235

  Nasnas, R ^a   Saliba, G ^b   Hallak, P ^c  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

^b SORBONNE UNIVERSITÉ   (France)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Colistin; Gram negative bacterial infections; Nosocomial infections

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; COLISTIN;

ABDOMINAL ABSCESS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CELLULITIS; CITROBACTER FREUNDII; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ENTEROBACTER CLOACAE; FRANCE; GRAM NEGATIVE BACTERIUM; HUMAN; MALE; MEDIASTINITIS; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OSTEOMYELITIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ABDOMINAL ABSCESS; ANTI-BACTERIAL AGENTS; COLISTIN; GRAM-NEGATIVE BACTERIA; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; OSTEOMYELITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PYELONEPHRITIS; RETROSPECTIVE STUDIES; URINARY TRACT INFECTIONS;

EID: 65349184513     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2007.09.013     Document Type: Article

References (51)

1. Li J., Nation R.L., Milne R.W., Turnidge J.D., and Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25 1 (2005) 11-25
2. Jain R., and Danziger L.H. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 38 9 (2004) 1449-1459
3. Livermore D.M. The need for new antibiotics. Clin Microbiol Infect 10 Suppl 4 (2004) 1-9
4. Falagas M.E., Bliziotis I.A., Kasiakou S.K., Samonis G., Athanassopoulou P., and Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 5 1 (2005) 24
5. Falagas M.E., and Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40 9 (2005) 1333-1341
6. Karabinis A., Paramythiotou E., Mylona-Petropoulou D., et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis 38 1 (2004) e7-e9
7. Littlewood J.M., Koch C., Lambert P.A., et al. A ten year review of colomycin. Respir Med 94 7 (2000) 632-640
8. Conway S.P., Brownlee K.G., Denton M., and Peckham D.G. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2 4 (2003) 321-332
9. Young M.L., Bains M., Bell A., and Hancock R.E. Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques. Antimicrob Agents Chemother 36 11 (1992) 2566-2568
10. Nicas T.I., and Hancock R.E. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol 143 2 (1980) 872-878
11. Groisman E.A., Kayser J., and Soncini F.C. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J Bacteriol 179 22 (1997) 7040-7045
12. Conrad R.S., and Galanos C. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance. Antimicrob Agents Chemother 33 10 (1989) 1724-1728
13. Vaara M., Vaara T., Jensen M., et al. Characterization of the lipopolysaccharide from the polymyxin-resistant pmrA mutants of Salmonella typhimurium. FEBS Lett 129 1 (1981) 145-149
14. Vaara M., Vaara T., and Sarvas M. Decreased binding of polymyxin by polymyxin-resistant mutants of Salmonella typhimurium. J Bacteriol 139 2 (1979) 664-667
15. Gatzeva-Topalova P.Z., May A.P., and Sousa M.C. Crystal structure of Escherichia coli ArnA (PmrI) decarboxylase domain. A key enzyme for lipid A modification with 4-amino-4-deoxy-L-arabinose and polymixin resistance. Biochemistry 43 42 (2004) 13370-13379
16. Mathur J., and Waldor M.K. The Vibrio cholerae ToxR-regulated porin OmpU confers resistance to antimicrobial peptides. Infect Immun 72 6 (2004) 3577-3583
17. Falagas M.E., and Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10 1 (2006) R27
18. Conway S.P., Pond M.N., Watson A., Etherington C., Robey H.L., and Goldman M.H. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax (1997) 1987-1993
19. Kunin C.M., and Bugg A. Binding of polymixin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis (1971) 394-400
20. Craig W.A., and Kunin C.M. Dynamics of binding and release of the polymixin antibiotics by tissues. J Pharmacol Exp Ther (1973) 757-765
21. Ledson M.J., Gallagher M.J., Cowperthwaite C., Convery R.P., and Walshaw M.J. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 12 3 (1998) 592-594
22. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 7 6 (2001) 434-440
23. Wolinsky E., and Hines J.D. Neurotoxic and nephrotoxic effects of clolistin in patients with renal disease. N Engl J Med 266 (1962) 759-762
24. Ryan K.J., Schainuck L.I., Hickman R.O., and Striker G.E. Colistimethate toxicity. Report of a fatal case in a previously healthy child. JAMA 207 11 (1969) 2099-2101
25. Koch-Weser J., Sidel V.W., Federman E.B., Kanarek P., Finer D.C., and Eaton A.E. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72 6 (1970) 857-868
26. Bosso J.A., Liptak C.A., Seilheimer D.K., and Harrison G.M. Toxicity of colistin in cystic fibrosis patients DICP. Ann Pharmacother 25 11 (1991) 1168-1170
27. Hamer D.H. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Resp Crit Care Med (2000) 328-330
28. Hoeprich P.D. The polymixins. Med Clin North Am 54 5 (1970) 1257-1265
29. Tripathi V.N., Stulberger E.A., and Takacs F.J. Colistimethate over dosage. J Urol (1970) 176-178
30. Chen C.C., and Feingold D.S. Locus of divalent cation inhibition of the bactericidal action of polymixin B. Antimicrob Agents Chemother (1972) 331-335
31. Ouderkirk J.P., Nord J.A., Turett E.S., and Kislak J.W. Polymixin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother (2003) 2659-2662
32. Evans M.E., Feola D.J., and Rapp R.R. Polymixin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother (1999) 960-967
33. Koch-Weser J., Sidel V.W., Federman E.B., Kanarek P., Fioner D., and Eaton A. Adverse effects of sodium colistimethate. Ann Intern Med (1970) 857-868
34. st century?. Clin Infect Dis (2002) 901-902
35. Price D.J., and Graham D.I. Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J (1970) 525-527
36. Boutiba-Ben Boubaker I., Boukadida J., Triki O., Hannachi N., and Ben Redjeb S. Outbreak of nosocomial urinary tract infections due to a multidrug resistant Pseudomonas aeruginosa. Pathol Biol (2003) 147-150
37. Rio Y., Pina P., Jurin F., et al. Susceptibility of Pseudomonas aeruginosa to antibiotics isolated from patients of intensive care units in France in 1998. Resistant phenotypes to beta-lactams. Pathol Biol (2002) 12-17
38. Linden P.K., Kusne S., Coley K., Fontes P., Kramer D.J., and Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis (2003) 154-160
39. Littlewood J.W., Koch C., Lambert P.A., et al. A ten-year review of Colomycin. Respir Med (2000) 632-640
40. Nikaido H. Antibiotic resistance caused by Gram-negative multidrug efflux pumps. Clin Infect Dis Suppl 1 (1998) S32-S41
41. Horton J., and Pankey G. Polymixin B, colistin and sodium colistimethate. Med Clin North Am (1982) 135-142
42. Gough M., Hancock R.E., and Kelly N.M. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun (1996) 4922-4927
43. Stokes D.C., Shenep J.L., Fishman M., Hildmer W.K., Bysani G.K., and Rufus K. Polymixin B prevents lipopolysaccharide-induced release of tumor necrosis factor-alpha from alveolar macrophages. J Infect Dis (1989) 52-57
44. Cavaillon J.M., and Haeffner-Cavaillon N. Polymixin B inhibition of LPS-induced interleukin-1 secretion by human monocytes is dependant upon the LPS origin. Mol Immunol (1986) 965-969
45. Li J., Nation R.L., Turnidge J.D., et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negativebacterial infections. Lancet Infect Dis 6 9 (2006) 589-601
46. Markou N., Apostolakos H., Koumoudiou C., et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7 5 (2003) R78-R83
47. Reina R., Estenssoro E., Saenz G., et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31 8 (2005) 1058-1065
48. Michalopoulos A.S., Tsiodras S., Rellos K., Mentzelopoulos S., and Falagas M.E. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11 2 (2005) 115-121
49. Falagas M.E., Rizos M., Bliziotis I.A., Rellos K., Kasiakou S.K., and Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 105 1 (2005) 1
50. Levin A.S., Barone A.A., Penço J., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28 5 (1999) 1008-1101
51. Garnacho-Montero J., Ortiz-Leyba C., Jiménez-Jiménez F.J., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36 9 (2003) 1111-1118